Recent studies have implicated the dying cell as a potential reservoir of modified autoantigens that might initiate and drive systemic autoimmunity in susceptible hosts. The spliceosomal Sm proteins are recognized by the so-called anti-Sm autoantibodies, an antibody population found exclusively in patients suffering from systemic lupus erythematosus. We have studied the effects of apoptosis on the Sm proteins and demonstrate that one of the Sm proteins, the Sm-F protein, is proteolytically cleaved in apoptotic cells. Cleavage of the Sm-F protein generates a 9-kDa apoptotic fragment, which remains associated with the U snRNP complexes in apoptotic cells. Sm-F cleavage is dependent on caspase activation and the cleavage site has been located near the C-terminus, EEED 81 kG. Use of different caspase inhibitors suggests that besides caspase-8 other caspases are implicated in Sm-F cleavage. A C-terminally truncated mutant of the Sm-F protein, representing the modified form of the protein, is capable of forming an Sm E-F-G complex in vitro that is recognized by many anti-Sm patient sera.
Introduction
Systemic autoimmune diseases are characterized by the production of autoantibodies directed towards a wide range of self-antigens. The mechanisms by which these autoantigens escape immunological tolerance are still largely unknown, although a number of recent observations suggest that modified self-antigens that are generated during cell death, apoptosis [1] [2] [3] [4] [5] [6] [7] or necrosis, 8 may play an important role in the development of autoimmunity. In the past few years, many proteins and protein complexes that are autoantigenic in autoimmune patients have been described to be uniquely modified during apoptosis. 3 The best-characterized type of modification of autoantigenic proteins that occurs during apoptosis is proteolytic cleavage, which is largely mediated by caspases 9, 10 or by granzyme B.
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Other post-translational modifications of autoantigens that occur during apoptosis have been described, such as hyperphosphorylation, dephosphorylation, citrullination, crosslinking by transglutaminase, poly(ADP-ribosyl)ation, methylation, and deacetylation, (reviewed in Utz and Anderson 1 , Utz et al.
, Doyle and Mamula 7
). It has been postulated that such post-translational modifications of autoantigens may uncover cryptic epitopes and/or create novel epitopes to which no tolerance exists, and in this way could provoke an autoimmune response in susceptible individuals. [1] [2] [3] [4] [5] [6] Based on this hypothesis, the modifications brought upon autoantigens during cell death represent the initial epitopes to which a primary immune response is generated. This response is followed by secondary responses and epitope spreading to unmodified regions of the autoantigens and antigens associated with the initially modified antigen. 6 Patients suffering from systemic lupus erythematosus (SLE) spontaneously produce autoantibodies against a multitude of cellular components. Antibodies against the spliceosomal Sm proteins, the so-called anti-Sm autoantibodies, are SLE-specific, in contrast to most other SLE-associated autoantibody populations. 14 The Sm proteins B/B 0 , D1, D2, D3, E, F, and G are core components of the small nuclear ribonucleoproteins (snRNPs) U1, U2, U4/U6, and U5, which are essential for the splicing of pre-mRNAs in eukaryotes. 15 The parallel recognition of several Sm proteins by anti-Sm patient sera is not only due to distinct antibody populations, but also to cross-reactive epitopes on the Sm proteins, thus indicating that the Sm proteins share structural homology. Indeed, all Sm proteins contain an evolutionarily conserved region of 70-90 amino acids, designated Sm domain, which contains the Sm1 and the Sm2 sequence motifs.
cally immunoprecipitate the E-F-G ternary complex. 19 Therefore, it was concluded that the E, F, and G proteins might harbor immunodominant antigenic determinants that are expressed exclusively or predominantly on the assembled E-F-G complex. 19 At present, no modifications specifically occurring on the Sm proteins during apoptosis have been reported. In this study, we demonstrate that the Sm-F protein is cleaved during apoptosis. Furthermore, the role of caspases in Sm-F cleavage was investigated and the cleavage site mapped. The possible consequences of the apoptotic modification of a Sm protein for the generation of anti-Sm autoantibodies in SLE patients are discussed.
Results

Cleavage of the Sm-F protein during anti-Fas induced apoptosis
In order to study potential molecular changes in the Sm proteins during apoptosis, Jurkat cells were treated with the agonistic anti-Fas antibody 7C11 and analyzed by Western blotting using different anti-Sm patient sera or polyclonal rabbit antisera raised against individual Sm proteins. Sm-B/B 0 , D, E, and G proteins were not detectably altered during antiFas induced apoptosis ( Figure 1a and data not shown). However, using the patient serum B156, which recognizes the Sm-F protein (11 kDa) in immunoblot, an Sm-F-specific band with an apparent molecular weight of 9-kDa was observed, which would be consistent with proteolytic cleavage of Sm-F protein ( Figure 1a ). The B156 serum has an anti-U1RNP/antiSm serotype 14 recognizing the specific U1 proteins, U1-70K and U1C, and the Sm-B/B 0 , Sm-D, and Sm-F proteins. The identity of the Sm-F protein was confirmed by Western blot analysis using a specific anti-Sm-F polyclonal rabbit serum (Figure 1b) . Interestingly, the anti-Sm-F rabbit serum displayed a relatively weak reactivity with the 9-kDa Sm-F species in apoptotic cell extracts (Figure 1b, lanes 2 and 3) .
To support the correlation between Sm-F cleavage and execution of the apoptotic cascade after Fas stimulation, we compared the appearance of the Sm-F 9-kDa fragment in cell lysates derived from Fas-stimulated Jurkat cells (Jurkat/Neo) and cells overexpressing Bcl-2 (Jurkat/Bcl-2). As expected, apoptosis after anti-Fas treatment was strongly delayed in Jurkat/Bcl-2 as compared to Jurkat/Neo. [20] [21] [22] [23] In Jurkat/Neo cell lysates, the conversion of Sm-F into a 9-kDa fragment was clearly detectable after 2 h of anti-Fas treatment and was complete after 8 h of anti-Fas treatment (Figure 1c, lanes 1-3) . In contrast, in anti-Fas treated Jurkat/Bcl-2 cells, the 9-kDa Sm-F fragment was only detectable after 8 h and represented only a minor fraction of the total amount of Sm-F protein (Figure 1c, lanes 4-6) . U1-70K protein is one of the prototypic autoantigens known to be cleaved during apoptosis. 21 Therefore, we compared the fate of Sm-F and U1-70K proteins in the same apoptotic lysates, using a patient serum reactive with U1-70K. 22, 23 As shown in Figure 1d , cleavage of the U1-70K protein into a 40 kDa fragment was observed with the same kinetics after Fas-ligation as the cleavage of Sm-F protein.
A variety of apoptosis stimuli lead to Sm-F cleavage in various cell types
To investigate whether cleavage of the Sm-F protein is a general feature of apoptotic cells, we analyzed cell lysates from several cell types exposed to different apoptotic stimuli. Jurkat cells were exposed to Fas-ligand, cycloheximide, or anisomycin ( Figure 2, lanes 1-4) Sm-F cleavage product remains associated with the U snRNP complexes in apoptotic cells
To investigate whether the Sm-F cleavage product remains associated with the U snRNP complexes in apoptotic cells, we immunoprecipitated these complexes from control and apoptotic Jurkat cell extracts using monoclonal antibodies directed to the U1 snRNP-specific proteins U1A (mAb 9A9, which also recognizes U2B 00 ) and U1-70K (mAb 2.73), to the Sm proteins (mAb Y12), to Sm-D1 (mAb KSm2), to U2B 00 (mAb 4G3) and polyclonal antibodies to the TMG-cap of the snRNAs (H20). Immunoprecipitates were subsequently analyzed by immunoblotting using the anti-Sm patient serum B156. In all cases, the Sm-F cleavage product was found in the immunoprecipitate (Figure 3 ). This indicates that the Sm-F protein is cleaved while associated with the intact U snRNP complexes in apoptotic cells and remains associated with these complexes. Neither Sm-F nor its cleavage product was precipitated by a control antibody (anti-Ro60, lanes 15 and 16).
Sm-F cleavage is caspase-mediated
Since the activation of caspases is one of the major biochemical features of the execution phase of apoptosis, we investigated whether caspase activation was required for Sm-F cleavage. Jurkat cells were cultured in the presence of Figure 3 The apoptotic cleavage product of Sm-F remains associated with the U snRNP complexes. U snRNP complexes were immunoprecipitated from control and apoptotic (8 h incubated with anti-Fas antibody) Jurkat cell extracts using anti-TMG cap rabbit serum (H20) and the monoclonal antibodies Y12 (anti-Sm), 2.73 (anti-U1-70K), KSm2 (anti-Sm-D1), 9A9 (anti-U1A/U2B 00 ), 4G3 (anti-U2B 00 ), and 1D11 (anti-Ro60). Immunoprecipitates were analyzed by 15% SDS-PAGE and Western blotting using the anti-Sm patient serum B156. The positions of the Sm-F protein (closed arrowhead) and its cleavage product (open arrowhead) are indicated on the left. In lanes 1 and 2 input samples, 20% of the total control and apoptotic cell extracts, respectively, were loaded various tetrapeptide inhibitors of caspases for 1 h prior to the induction of apoptosis by the addition of anti-Fas antibody, after which cells were cultured for 8 h. We used caspase inhibitors that are representative for the different groups of caspases: Ac-YVAD-CMK for group I caspases (caspase-1-like), z-DEVD-FMK for group II caspases (caspase-3-like), or Z-IETD-FMK (caspase-8) and Z-LEHD-FMK (caspase-9) for group III caspases. Cell extracts were analyzed by Western blotting using the anti-Sm patient serum B156. The cleavage of Sm-F was (almost) completely inhibited in the presence of 2 or 20 mM of Ac-YVAD-CMK, Z-DEVD-FMK, or Z-IETD-FMK inhibitors ( Figure 4 , lanes 4-9). In the presence of the Z-LEHD-FMK inhibitor Sm-F cleavage was partially inhibited at 2 mM and almost completely inhibited in the presence of a 10-fold higher concentration ( Figure 4 , lanes 10-11). As a control for the inhibitory activity of the tetrapeptide inhibitors, cell extracts were also analyzed for U1-70K cleavage. 22 The inhibition of U1-70K cleavage appeared to be very similar to that observed for Sm-F (data not shown). These results suggest that different caspases or proteases activated by caspases are involved in Sm-F cleavage in apoptotic Jurkat cells.
In another approach to examine if caspases are crucial for Sm-F cleavage, we analyzed the fate of Sm-F in a cellular model of caspase-independent necrotic cell death 24, 25 using Jurkat JB6 cells 26 that die necrotically when treated with dsRNA. 27 No cleavage of Sm-F was observed in these cells, indicating that Sm-F is not the result of mere cell demise and supporting the involvement of caspases in the cleavage of the Sm-F protein rather than another proteolytic system active in necrotic cell death (data not shown).
To determine whether recombinant caspases can process the Sm-F protein, in vitro translated 35 S-labeled Sm-F was incubated with recombinant murine caspases-1, -2, -3, -6, -7, -8 and -11. 28 Reaction products were analyzed by SDSpolyacrylamide gel electrophoresis (PAGE) followed by autoradiography. Caspases-1 and -8, but not -2, -3, -6, -7 and -11, cleaved the Sm-F protein, generating a 9-kDa cleavage product, with an electrophoretic mobility indistinguishable from that of the Sm-F fragment in apoptotic cell extracts ( Figure 5a and data not shown). Caspase-1 induced only a weak cleavage of Sm-F, while caspase-8 was much more efficient ( Figure 5a, lanes 2 and 7) . In vitro cleavage of 35 S-labeled PARP was performed as a control for the activity of the recombinant caspases (Figure 5a, lanes 9-16) . All the caspases cleaved PARP except caspase-2, which was checked to be active with an Ac-DEVD-amc fluorogenic substrate
28 (data not shown). To evaluate the difference in activity of caspases-1 and -8 (and caspase-3 as a negative control) on the Sm-F protein more extensively, a dilution series of these caspases was incubated for 1.5 h with radiolabeled Sm-F or PARP. The results in Figure 5b show that caspase-8 was about 10 times more efficient than caspase-1 in cleaving the Sm-F protein (lanes 2-7), whereas the efficiency of PARP cleavage was about equal (lanes [13] [14] [15] [16] [17] [18] .
Taken together these data indicate that Sm-F is a caspase substrate and that in vitro caspase-8 cleaves Sm-F most efficiently. To verify if caspase-8 is crucial for the processing of Sm-F in apoptotic cells, we made use of caspase-8-deficient Jurkat cells, as confirmed by immunoblotting (data not shown). These cells respond apoptotically when treated with staurosporine in combination with cycloheximide. Despite the absence of caspase-8, the same Sm-F cleavage pattern was observed as in staurosporin-treated parental cells (Figure 5c, lanes 3-4) . From this, we concluded that other caspases than caspase-8 can cleave Sm-F in apoptotic cells, in agreement with the in vitro proteolysis results using recombinant caspases.
Identification of the caspase cleavage site in Sm-F Analysis of the Sm-F sequence (Figure 6a ) revealed the presence of three potential caspase cleavage sites, two of which are located near the middle of the primary structure and the third located close to the C-terminus. Taking into account the apparent size of the cleavage product, we speculated that the 78 EEED 81 sequence near the C-terminus of Sm-F is the most likely target for caspases. Indeed, the substitution of aspartic acid 81 by an alanine confirmed this hypothesis, because this mutant of Sm-F was neither cleaved by recombinant caspase-1 nor by caspase-8 in vitro, in contrast to wild-type Sm-F (Figure 6b) . A C-terminally truncated mutant of the Sm-F protein comprising amino acids 1-81, which was analyzed in parallel with the in vitro cleaved Sm-F (Figure 6b, lane 9) , co-migrated with the Sm-F fragment generated by caspase cleavage, consistent with cleavage at aspartate-81. Taken together, these data indicate that the 78 EEED 81 sequence indeed represents the caspase cleavage site in the Sm-F protein.
Anti-Sm patient sera recognize the Sm-F apoptotic fragment individually and assembled into a complex with the Sm-E and Sm-G proteins
To investigate whether the apoptotic Sm-F cleavage product is recognized by anti-Sm patient sera that are not reactive with the Sm-F protein on immunoblots, we used the in vitro translated Sm proteins E, F, G, and the C-terminal deletion mutant FD81 for immunoprecipitation experiments. 35 S-labeled in vitro translated proteins were incubated individually (Figure 7b-h, lanes 1-4) or combined to allow E-F-G complex formation 19 ( Figure 7b -h, lanes 5 and 6), and subsequently immunoprecipitated with preselected anti-Sm patient sera, with the anti-Sm Y12 mAb or with a nonimmune serum. Interestingly, the Sm-F C-terminally truncated mutant was able to assemble into a complex with the E and G proteins in vitro (designated E-F*-G complex). The results in Figure 7 show that all the sera tested were able to precipitate the individual proteins as well as the E-F-G and E-F*-G complexes. However, as reported previously, 19 most antiSm patient sera and mAb Y12 precipitated the E-F-G complex (and the E-F*-G complex) considerably more efficiently than the individual proteins, suggesting that an important subset of anti-Sm patient autoantibodies recognizes conformational epitopes located on the E-F-G (or E-F*-G) complex itself. In total, 25 anti-Sm patient sera were tested for their ability to immunoprecipitate the E-F-G and the E-F*-G complexes. Although differences in precipitating efficiency between the various sera were observed, the overall result was that no significant differences in precipitation efficiency of both complexes were observed (Figure 7b -g, lanes 5 and 6, and data not shown).
Discussion
In the past few years, a role for apoptosis in the development of autoimmunity has been suggested. At present, many autoantigens have been found that are modified during apoptosis. 3 A current hypothesis is that these intracellularmodified autoantigens become exposed to the immune system because of massive cell death and/or inefficient removal of dying cells, leading to a specific primary immune response against the modified epitopes of the self-antigens, followed by secondary responses and epitope spreading to unmodified regions of the autoantigens and antigens associated with the initially modified antigen.
1,2,6 SLE patients develop autoantibodies against a wide variety of intracellular antigens such as the components of the U1 snRNP complex, including the spliceosomal Sm proteins.
14 In this report, we demonstrate for the fist time that one of the Sm proteins, the Sm-F protein, is cleaved in apoptotic cells in a caspasea b By analyzing the U1 snRNP complex during anti-Fas induced apoptosis, we demonstrated that it is likely that the Sm-F protein is cleaved while it is associated with the intact U1 snRNP complex in apoptotic cells, and that the N-terminal 9-kDa fragment remains associated with the U1 snRNP complex. The conserved Sm motif in the Sm-F protein, composed of Sm1 (position 19-50) and Sm2 (position 59-72) motifs, 16 mediates the Sm-F interaction with the U snRNA's Sm site. 15 Cleavage of Sm-F after the aspartic residue at position 81, as deduced from the in vitro cleavage experiments using recombinant caspases, removes the last five Cterminal amino-acid residues of Sm-F. Cleavage at this position leaves the Sm motifs intact, consistent with the finding that truncated Sm-F is associated with the U1 snRNP complexes in apoptotic cells. Antibodies against the TMG cap of the snRNAs, which is removed from the U1 snRNA in apoptotic cells but not from the other snRNAs (U2, U4/U6 and U5), 22 and antibodies against the U2 snRNA associated B 00 protein were also capable of coimmunoprecipitating the Sm-F product from apoptotic Jurkat cell lysates. Therefore, the Sm-F protein is probably cleaved not only in the U1 snRNP complex (which is the major autoantigenic complex) but also in the other U snRNP complexes. In agreement with this, the total pool of Sm-F protein appeared to be cleaved in Jurkat cells. Structural information on the common part of the Sm proteins and on their complexes has been obtained by crystallographic analyses of the D 3 B and D 1 D 2 complexes. 29 Based upon the experimental data, the Sm proteins were proposed to arrange in a heptamer ring formed by pairwise Sm protein interactions. Interestingly, in this structural model for the Sm complex the C-terminal 11 amino acids of the Sm-F protein (aa 76-86) are predicted to extend from the outer surface of the ring, whereas the RNA component of the U snRNP is positioned in the central hole of the ring. 30 This structural model is fully consistent with the complete accessibility of the Sm-F cleavage site (aa 81) for caspases when the Sm-F protein is assembled into U snRNPs.
We have tried to address the nature of the caspase implicated in Sm-F cleavage by treating apoptotic cells with different synthetic tetrapeptide caspase inhibitors and by using a panel of purified recombinant caspases in vitro. Based on these results caspase-8 appeared to be a good candidate protease for Sm-F cleavage in the apoptotic cell, since it was the most efficient protease in generating the 9 kDa-fragment in vitro. However, the generation of this Sm-F fragment in apoptotic lysates of caspase-8-deficient Jurkat cells treated with staurosporin and the results from the peptide inhibitor studies in apoptotic cells (Figure 4) , demonstrated that other caspases than caspase-8 are implicated in Sm-F proteolysis as well. We conclude that care should be taken when comparing in vitro and in vivo caspase cleavage data for cellular substrates. In a cellular context, accessibility of the cleavage site in the substrate and subcellular localization likely are principal determinants in defining a caspasesubstrate pair.
Cleavage of Sm-F occurs at the rather unconventional caspase cleavage site EEED 81 . The optimal tetrapeptide sequence for recognition by caspase-8, for instance, has been determined to be LE(T/V)D and for caspase-1 31,32 Nonetheless, caspase cleavage at unconventional sites, including EEED 170 in DNA topoisomerase 1, has already been reported previously. 33, 34 The Sm proteins are essential for the splicing of pre-mRNAs in eukaryotes. 15 The significance of Sm-F cleavage for the progression of the apoptotic process is unclear. It has been suggested that cleavage of U1-70K, another component of the autoantigenic U1 snRNP complex, abolishes its function during pre-mRNA splicing as an enhancer of the interaction between the U1 snRNP complex and the 5 0 -splice site of an exon, thus abrogating the process of mRNA splicing. 13, 35 Whether removal of the carboxyterminal part of Sm-F would impair its function in mRNA splicing will require further studies.
Recent studies have led to the hypothesis that modifications brought upon autoantigens during cell death represent the initial epitopes to which an immune response is generated. 1, 6 Apart from the Sm-F cleavage reported here, three other apoptosis-associated modifications have been described for components of the U1 snRNP complex, a major autoantigen in SLE and SLE-overlap syndromes. These modifications are cleavage of the U1-70K protein 21 , hyperphosphorylation of the associated SR proteins, 36 and cleavage of the U1 snRNA. 22 Exposure of elevated and persistent levels of apoptotically modified U1 snRNP to the immune system of a susceptible individual could lead to breaking of the immunological tolerance to the U1 snRNP complex, with subsequent production of autoantibodies to components of this complex in patients with SLE and SLE-overlap syndromes. 1, 2, 6 It has been demonstrated recently that autoantibodies specific for the apoptotic form of U1-70K exist even in patient sera without autoantibodies to the complete U1-70K. 37 This indicates that the apoptotic form of U1-70K displays B cell epitopes that are not displayed on the fulllength U1-70K and that an immune response to apoptotic U1-70K may precede responses to intact U1-70K. This report clearly shows that immunity to apoptotically modified proteins can develop against caspase-cleaved forms of autoantigenic proteins. 37 Interestingly, many anti-Sm patient sera recognize the modified form of Sm-F, individually or in the E-F*-G complex, as demonstrated by immunoblot and immunoprecipitation data obtained with the truncated mutant Sm-FD81. We have tried to demonstrate the relevance of Sm-F cleavage for antiSm autoimmunity in several ways without conclusive results. A possible explanation is that autoantibodies specifically targeting the modified form of Sm-F reported here are only prominently present in patient sera during early stages of the disease, since the modified epitopes are supposed to trigger the autoimmune response. The anti-Sm sera we used were of established SLE patients, but future approaches, including the use of serum samples of patients in a very early phase of the disease, could provide evidence that cleavage of Sm-F contributes to breaking of the immunological tolerance to the Sm proteins and the subsequent generation of anti-Sm autoantibodies in SLE patients.
Materials and Methods
Cell lines
Jurkat cells (human T-cell leukemia), control JA3 and caspase-8-deficient Jurkat cells (kindly provided by Dr. J Blenis), Ramos B cells (Burkitt's lymphoma), CCRF-CEM and MOLT-4 (human T-cell lymphoblastic leukemia cell lines), and Jurkat JB6 cells (kindly provided by Dr. S Nagata and Dr. H Matumura) were grown in RPMI-1640 medium (Gibco-BRL) supplemented with 10% heat-inactivated fetal calf serum (FCS), 1 mM sodium-pyruvate, penicillin, and streptomycin. Jurkat cells stably transfected with Bcl-2 (Jurkat/Bcl-2) (kindly provided by Dr. J Reed, La Jolla, CA, USA) or with the empty transfection vector (Jurkat/Neo) were cultured in the same medium with the addition of 200 mg/ml G418 (Gibco-BRL). HeLa (human cervix carcinoma) cells and HEp-2 (human larynx carcinoma) cells were grown in DMEM supplemented with 10% heatinactivated FCS, penicillin, and streptomycin. Cells were cultured in 5% CO 2 at 371C. 
Patient serum samples
Induction of cell death
To induce apoptosis, Jurkat cells were treated with the agonistic anti-Fas monoclonal antibody 7C11 supernatant (final dilution of 1 : 500) (kindly provided by Dr. M Robertson, Bloomington, IN, USA), 23 with murine Fasligand supernatant as described 22 (final dilution of 1 : 30) (gift of Dr. A Fontana, Zürich, Switzerland), with 10 mg/ml anisomycin or with 100 mg/ml cycloheximide. HeLa cells and HEp-2 cells were treated with 0.5 mg/ml actinomycin D and anti-Fas antibody or with actinomycin D and 5000 IU/ml recombinant human TNFa. Ramos and CCRF-CEM were treated with actinomycin D, anisomycin, and cycloheximide. CCRF-CEM cells were also treated with anti-Fas antibody. Apoptosis was induced in the MOLT-4 cells by g-irradiation using a dose of 5 Gy. Control JA3 and caspase-8-deficient Jurkat cells were treated with staurosporin (400 nM) and cycloheximide (10 mg/ml). The extent of induced apoptosis was assessed by flow cytometry using annexin V-FITC and propidium iodide (PI) staining as described previously. 22, 23 After 8 h generally more than 90% of the cells were apoptotic. Jurkat JB6 cells were induced to necrosis by treatment with dsRNA (polyI,C) as described elsewhere. 27 Cells were incubated at 371C for 2-24 h prior to harvesting. After induction of cell death, cells were washed two times with PBS and used immediately or stored at À701C. For experiments utilizing the cell-permeable tetrapeptide caspase inhibitors (Calbiochem), Jurkat cells were cultured for 1 h in the presence of 2 or 20 mM Ac-YVAD-CMK, Z-DEVD-FMK, Z-IETD-FMK, or Z-LEHD-FMK (irreversible inhibitors of caspases-1, -3/-7, -8, and -9, respectively) in dimethylsulfoxide (DMSO). The specificity of these inhibitors is based on in vitro assays with purified caspases and in this way their specificity in a cellular context is difficult to define. Subsequently, apoptosis was induced by the addition of anti-Fas monoclonal antibody followed by harvesting the cells after 8 h of incubation.
Western blot analysis
Cells were lysed on ice for 30 min in NP-40 lysis buffer (25 mM Tris-HCl, pH 7.5, 1% NP-40, 100 mM KCl, 10 mM MgCl 2 , 1 mM dithiothreitol (DTT)), containing a protease inhibitor cocktail (Roche). Cell lysates were centrifuged for 15 min at 41C (12 000g) and the supernatants were used immediately or stored at À701C. Protein extracts of 1 Â 10 6 cells were analyzed by 15% SDS-PAGE and Western blotting using SLE patient serum B156 (anti-Sm-F) or H42 (anti-U1-70K), anti-SmF rabbit serum (kindly provided by Dr. Reinhard Lührman and Dr. Hero Brahms, MaxPlanck Institute of Biophysical Chemistry, Göttingen, Germany) or anticaspase-8 mouse mAb (PharMingen, San Diego, CA, USA), followed by detection by chemoluminescence.
Immunoprecipitation
Protein A-agarose beads (20 ml of 50% slurry, Pharmacia) were coated with 200 ml culture supernatant of the following mouse monoclonal antibodies: Y12 (anti-SmB/B 0 /D1/D3), 39 KSm2 (anti-SmD1), 40 2.73 (anti-U1-70K), 41 9A9 (anti-U1A/U2B 00 ), 4G3 (anti-U2B 00 ), 2G10 (anti-Ro60), or with 20 mg of anti-2,2,7-trimethylguanosine (TMG) cap rabbit polyclonal antibodies (H20) (Euro-Diagnostica BV, Arnhem, The Netherlands). Incubations were performed overnight at 41C in IPP150 (150 mM NaCl, 10 mM Tris-HCl pH 8.0, 0.1% NP-40) by end-over-end rotation. Between incubations, beads were washed three times with IPP150. Immunoprecipitations were carried out with 20 ml (2 Â 10 6 cell equivalents) of Jurkat extract (control or apoptotic) in IPP150 by end-over-end rotation for 2 h at 41C and subsequently washed three times with IPP150. The beads were resuspended in Laemmli buffer to analyze protein complexes using SDS-PAGE and Western blotting.
Plasmids
A full-length cDNA of Sm-F cloned into the EcoRI and SalI sites of pBluescript KS+ vector (pBLSF) was kindly provided by Dr. Reinhard Lührmann and Dr. Hero Brahms (Max-Planck Institute of Biophysical Chemistry, Göttingen, Germany). Two mutant cDNAs were generated, one encoding a C-terminally truncated Sm-F protein (FD81), which corresponds to the largest apoptotic Sm-F fragment generated in vivo, and another encoding a substitution mutant of Sm-F in which the aspartic acid at position 81 was substituted by an alanine. Both mutants were generated by a PCR-based approach using pBLSF as a template and the following primers: 5 0 -GCGAATTCCACCATGAGTTTACCCCTCAATCCC-3 0 (corresponding to the N-terminal region of Sm-F; EcoRI site underlined), 5 0 -CCGTCGACCTATTCTCTCATTTCCCCAGCTTCTTCCT-3 0 (to generate the substitution mutant; SalI site underlined; mutation in bold), and 5 0 -CTGCCGGTCGACCTAATCTTCTTCCTCTTCTTCCAC-3 0 (to generate the deletion mutant; SalI site underlined). The resulting PCR products were purified, digested with EcoRI and SalI and were inserted into the EcoRI and SalI sites of pBluescript KS-. The integrity of the mutant constructs was confirmed by DNA sequencing. The pBLSE, pBLSG (kindly provided by Reinhard Lührmann, Göttingen, Germany), and pGemPARP constructs, which contain the complete human Sm-E, Sm-G, and PARP cDNAs, respectively, were used as template for transcription/ translation of the respective proteins.
Immunoprecipitation of in vitro translated proteins
Proteins were generated by in vitro transcription/translation of pBLSE, pBLSF, pBLSG, and pBLSFD81 templates using the TnT T7-coupled rabbit reticulocyte lysate system (Promega) as described by the manufacturer. For detection of the translation products, 35 S-methionine was added to the translation reactions. For each immunoprecipitation, 5 ml of in vitro translated E, F, G, and/or FD81 protein were incubated, either alone or in the combinations stated in the text, for 45 min at 301C. A measure of 5 ml of patient serum or of a normal human serum (as the negative control for each experiment) or 100 ml of culture supernatant of anti-Sm Y12 was then added to the radiolabeled protein sample, and the incubation was continued for an additional 30 min at room temperature. The mixture was transferred to another tube containing 10 ml of preswollen protein G-agarose (Pharmacia) in 400 ml of PBS/1% bovine serum albumin. Following incubation for 2 h at 41C with gentle agitation, the beads were washed five times with 10 mM Tris-HCl, pH 7.5, 0.05% NP-40, 150 mM NaCl, and once with water. Precipitated proteins were fractionated on 15% SDS-PAGE and visualized by autoradiography.
In vitro cleavage assay
In vitro translated Sm-F, Sm-F-D81A (substitution mutant), and PARP were incubated with 200 nM of the purified murine recombinant caspases 28 in a total volume of 25 ml CFS buffer (220 nM mannitol, 68 nM sucrose, 2 mM NaCl, 2.5 mM KH 2 PO 4 , 10 nM HEPES pH 7.4, 1 mM aprotinin, 1 mM leupeptin, and 1 mM PMSF, supplemented with 5 mM DTT) for 1.5 h at 371C. The resulting cleavage products were analyzed by 15% SDS-PAGE, followed by autoradiography. To compare the enzymatic activities of caspases-1, -8, and -3 on the Sm-F protein more accurately, a serial dilution of the enzymes (200, 66, and 22 nM) was incubated with the radiolabeled proteins in a total volume of 25 ml.
